Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25035106 | 0.84 | CRBN (0.41) | FFAR4HRH3 | |
| SCHEMBL30475476 | 0.84 | CRBN (0.41) | FFAR4HRH3 | |
| SCHEMBL25823606 | 0.82 | GRM5 (0.37) | GAASMN1; SMN2FFAR4MAPTALDH1A1 | |
| SCHEMBL24670689 | 0.72 | CRBN (0.44) | GAA | |
| SCHEMBL25935225 | 0.70 | CRBN (0.43) | PDE3BPDE3A | |
| SCHEMBL25447026 | 0.70 | FFAR4 (0.36) | GAAHPGDSMN1; SMN2FFAR4HRH3 | |
| SCHEMBL25035108 | 0.69 | CRBN (0.44) | SMN1; SMN2HRH3PDE3BPDE3AALDH1A1 | |
| SCHEMBL30475505 | 0.69 | CRBN (0.48) | HRH3PDE3BPDE3A | |
| SCHEMBL25823256 | 0.69 | CRBN (0.48) | HRH3PDE3BPDE3A | |
| SCHEMBL30475495 | 0.67 | CRBN (0.37) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | GAA 2658/4885HPGD 3219/4885SMN1; SMN2 3089/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | GAA 2669/4885HPGD 2409/4885SMN1; SMN2 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.